Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Harmonex Inc

Neither a doctor nor a teaching hospital

Research payments

$1,142,903

156 payments

Through program year 2025, Harmonex Inc is reported as receiving $1,142,903 in research payments, across 156 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $69,759 12
2024 Research $241,675 21
2023 Research $111,896 13
2022 Research $355,273 48
2021 Research $224,739 42
2020 Research $131,551 17
2019 Research $8,011 3

Breakdown

Who paid Research payments · program years 2019–2025
  1. Otsuka Pharmaceutical Development & Commercialization, Inc. $344,301 21 payments
  2. AbbVie, Inc. $320,727 23 payments
  3. Janssen Research & Development, LLC $176,198 39 payments
  4. Sage Therapeutics, Inc. $170,309 44 payments
  5. Purdue Pharma L.P. $59,390 13 payments
  6. Vanda Pharmaceuticals Inc. $22,776 5 payments
  7. ITI, Inc. $19,725 3 payments
  8. Adlon Therapeutics L.P. $13,910 2 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $7,817 4 payments
  10. Pfizer Inc. $7,748 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Multi-Center, Randomized, Controlled Trial to Evaluate the Effectiveness of A Digital Therapeutic (CT-152) As Adjunctive Therapy in Adult Subjects Diagnosed With Major Depressive Disorder $192,613 3 payments
  2. Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder $131,191 9 payments
  3. A Randomized Double Blind Placebo Controlled Parallel Group Multi Center Study Investigating the Efficacy Safety and Tolerability of JNJ42165279 in Adolescent and Adult Male Subjects with Autism Spectrum Disorder $130,554 27 payments
  4. Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder $97,884 5 payments
  5. A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment With Sage-217 in Adult Subjects With Major Depressive Disorder $96,949 30 payments
  6. Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States $51,570 10 payments
  7. A Comparative Study of Sage-217 Plus Sertraline Versus Placebo Plus Sertraline in Adults With Major Depressive Disorder $46,789 12 payments
  8. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder $39,237 2 payments
  9. A Long-Term, Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Flexible-Dose Brexpiprazole As Maintenance Treatment in Adolescent Patients With Schizophrenia $33,835 5 payments
  10. A Study to Obtain Biosensor Data from Janssen Autism Knowledge Engine in Children and Adults who are Typically Developing TD JAKE $30,149 10 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record